 Approximately 2,500 high-risk patients with an elevated LDL-C level 2.5 mmolL will be enrolled. Patients meeting all inclusion criteria and having none of the exclusion criteria at Visit 1 Screening will be included in the study. Eligible patients that agree to participate and sign an informed consent will be treated with either statin therapy increased or started or switched or combination of statin and ezetimibe 10 mg addedstarted as per Study Schematic Table 1 in order to achieve the recommended target of LDL2.5 mmolL and providing that this treatment is in the best interest of the patient. 